Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > RNA Diagnostic Test from Paraffin… >
RNA Diagnostic Test from Paraffin Improves Lung Cancer Diagnosis over Routine Microscopic Evaluation

Published: July 16, 2013.
By University of North Carolina Health Care
http://www.med.unc.edu

CHAPEL HILL, N.C. -- Knowing what type of lung cancer a patient has is critical to determine which drug will work best and which therapies are safest in the era of personalized medicine. Key to making that judgment is an adequate tumor specimen for the pathologist to determine the tumor's histology, a molecular description of a tumor based on the appearance of cells under a microscope. But not all specimens are perfect, and are sometimes so complex that a definitive diagnosis presents a challenge.

Scientists at the Universities of North Carolina and Utah have developed a histology expression predictor for the most common types of lung cancer: adenocarcinoma, carcinoid, small cell carcinoma and squamous cell carcinoma. This predictor can confirm histologic diagnosis in routinely collected paraffin samples of patients' tumors and can complement and corroborate pathologists' findings.

Their findings were reported in the July 2013 issue of the Journal of Molecular Diagnostics.

Neil Hayes, MD, MPH, associate professor of medicine and corresponding author of the study says, "As we learn more about the genetics of lung cancer, we can use that understanding to tailor therapies to the individual's tumor. Gene expression profiling has great potential for improving the accuracy of the histologic diagnosis. Historically, gene expression analysis has required fresh tumor tissue that is usually not possible in routine clinical care. We desperately needed to extend the analysis of genes (aka RNA) to paraffin samples that are routinely generated in clinical care, rather than fresh frozen tissue. That is the major accomplishment of the current study and one of the first large scale endeavors in lung cancer to show this is possible.

"Our predictor identifies the major histologic types of lung cancer in paraffin-embedded tissue specimens which is immediately useful in confirming the histologic diagnosis in difficult tissue biopsy specimens." Dr. Hayes is a member of UNC Lineberger Comprehensive Cancer Center.

The scientists used 442 samples of formalin-fixed paraffin-embedded specimens from lung cancer patients at UNC and the University of Utah Health Sciences Center as they developed their predictor.

First author Matthew Wilkerson, PhD, explains, "Our question was, 'Can histology be predicted accurately by gene expression?' We had lung cancer genes we already knew were differentially expressed in the different tumor types, so we measured them in tumor paraffin specimens. Next we developed a predictor in an independent set of tumor samples. We then compared the predictor to the actual clinical diagnosis and had additional pathologists review the samples. We showed accuracy as least as good as the pathologist. Our predictor exhibited a mean accuracy of 84 percent, and when compared with pathologist diagnoses, yielded similar accuracy and precision as the pathologists."

Dr. Hayes summarizes, "Going beyond meeting a current need of increasing the accuracy of histologic diagnosis is expected to be the ultimate benefit of this technology. There are many additional characteristics of tumors that could be leveraged for clinical purposes once the world of gene expression analysis from paraffin is efficient from clinical samples. We anticipate additional uses such as predicting responses to additional therapies and prognostication as near term additions."




Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Lung 
7/15/10 
New Method of Tissue Banking Makes Gene Analysis More Practical for Lung Cancer
By International Association for the Study of Lung Cancer
Analyzing the genes expressed by cancer cells allows for a better understanding of that patient's specific disease and in turn, a more personalized approach to treatment. But obtaining the …
Foundation 
12/14/10 
Antibiotic Selection Pressure And Macrolide Resistance in Nasopharyngeal Streptococcus Pneumoniae
By Public Library of Science
Jeremy Keenan and colleagues report that during a cluster-randomized clinical trial in Ethiopia, nasopharyngeal pneumococcal resistance to macrolides was significantly higher in communities randomized to receive azithromycin compared with …
Cancer 
8/28/14 
The Lancet Journals: Three-quarters of Depressed Cancer Patients Do Not Receive Treatment for Depression but a New Approach Could Transform Their Care
By The Lancet
Three papers published in The Lancet Psychiatry, The Lancet, and The Lancet Oncology reveal that around three-quarters of cancer patients who have major depression are not currently receiving treatment …
Woodrum 
4/14/13 
Icy Therapy Spot Treats Cancer in the Lung
By Society of Interventional Radiology
NEW ORLEANS (April 14, 2013)—Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The …
Wjg 
4/19/10 
Cystic Fibrosis And Crohn's Disease Treated Successfully with Infliximab
By World Journal of Gastroenterology
Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves …
Lung 
3/17/11 
New Therapy Found for Rare Lung Disorder
By University of Cincinnati Academic Health Center
CINCINNATI—Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found that the FDA-approved drug sirolimus, used primarily to prevent rejection in organ transplant patients, …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition